jackie.vuistiner

CUTISS awarded CHF 2.5M grant for automation program

CUTISS is delighted to announce that Innosuisse, the Swiss Innovation Agency, has awarded the company a CHF 2.5 million grant to advance our pioneering automation program. This grant will support the industrialization of denovoCast™, the world’s first machine that can bio-engineer large, personalized skin tissue grafts, in a fully closed way. This is yet another …

CUTISS awarded CHF 2.5M grant for automation program Read More »

CUTISS announces positive Phase 2 clinical trial results for denovoSkin™

CUTISS announces results from Phase 2 clinical trials for denovoSkin™ in adolescent and adult burn patients, and Phase 1 in children Phase 2 clinical trial reaches efficacy endpoint with high statistical significance for lead product denovoSkin™ in adult and adolescent burn patients. Phase 1 clinical trial of denovoSkin™ is completed with 5-year follow up demonstrating …

CUTISS announces positive Phase 2 clinical trial results for denovoSkin™ Read More »

Case report: Youngest patient ever treated with denovoSkin – a neonatal case

The paper published in Burns Open has presented the case of a four day-old neonate suffering from life threatening burns, involving 40% total body surface area burn. The patient received 260 cm2 of denovoSkin, covering 20% TBSA, as part of a clinical trial sub-study in Italy. The management of such cases represents an unprecedented challenge. …

Case report: Youngest patient ever treated with denovoSkin – a neonatal case Read More »

Advanced testing of human skin cells on the International Space Station to push the boundaries of innovation in regenerative medicine

As part of the company’s R&D in regenerative medicine, CUTISS will observe the effects of space on skin cells and tissue culture. Research implications towards human safety in space travel and new discoveries in regenerative medicine and tissue engineering on Earth. Four-week mission conducted in collaboration with SpacePharma which specializes in space-based experiments and micro-lab …

Advanced testing of human skin cells on the International Space Station to push the boundaries of innovation in regenerative medicine Read More »

BioVoice CUTISS interview with Dr. Daniela Marino

Following our presence at Arab Health 2023 we had the opportunity to speak with BioVoice, the top Indian bioscience news magazine. In the interview, our CEO Daniela Marino shared the progress that CUTISS has been making in bioengineering the personalized skin graft denovoSkin, the commercial plans around skin pigmentation, and the exciting innovations in regenerative …

BioVoice CUTISS interview with Dr. Daniela Marino Read More »

CUTISS to participate in Jefferies London Healthcare Conference 2022

Switzerland, 7 November 2022 – CUTISS AG, a Swiss clinical-stage life sciences company focused on skin regenerative medicine and tissue engineering, has announced that the company is invited to the upcoming Jefferies London Healthcare Conference, taking place November 15 – 17, 2022. Dr Daniela Marino, Chief Executive Officer and co-founder at CUTISS, will attend the conference …

CUTISS to participate in Jefferies London Healthcare Conference 2022 Read More »

Swiss RTS television reportage on innovation and denovoCast

More than a year since CUTISS announced the world’s first machine to bioengineer human skin, the news continues to generate interest and excitement. As part of their program focused on Swiss innovation, the broadcaster RTS (Neuchatel) visited CUTISS and CSEM who helped develop the denovoCast machine, to find out how automation can scale-up the production …

Swiss RTS television reportage on innovation and denovoCast Read More »

Scroll to Top

Newsletter

Would you like to contact us as a journalist?

©WyssZurich

This website uses cookies to ensure you get the best experience on our website.